Published in Nat Rev Cardiol on June 30, 2009
(64)Cu-labeled LyP-1-dendrimer for PET-CT imaging of atherosclerotic plaque. Bioconjug Chem (2014) 0.82
Genomic medicine for improved prediction and primordial prevention of cardiovascular disease. Arterioscler Thromb Vasc Biol (2013) 0.77
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med (1999) 16.30
Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med (2008) 14.01
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA (2003) 10.55
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA (2004) 9.91
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA (2006) 9.27
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 7.69
Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation (1997) 7.03
Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med (2007) 6.79
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA (2007) 6.02
Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 5.09
The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med (1998) 4.92
Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med (2006) 3.90
Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med (2007) 3.40
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA (2009) 3.33
Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA (2007) 3.12
ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation (2002) 3.05
Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A (2007) 2.99
Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation (1996) 2.54
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med (2007) 2.41
Noninvasive assessment of plaque morphology and composition in culprit and stable lesions in acute coronary syndrome and stable lesions in stable angina by multidetector computed tomography. J Am Coll Cardiol (2006) 2.36
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation (2001) 2.30
In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke (2004) 2.06
Histopathology of carotid atherosclerotic disease. Neurosurgery (2006) 2.05
Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation (2007) 2.04
Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by near-infrared spectroscopy. Circulation (2002) 1.94
Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression. Circulation (2007) 1.88
Prognostic significance of progression of coronary atherosclerosis. Circulation (1993) 1.79
Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol (2001) 1.78
The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin (2006) 1.53
Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation (2005) 1.50
Monitoring cancer treatment with PET/CT: does it make a difference? J Nucl Med (2007) 1.45
Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation (2004) 1.45
Characterization of non-calcified coronary atherosclerotic plaque by multi-detector row CT: comparison to IVUS. Atherosclerosis (2006) 1.41
Association of coronary disease with segment-specific intimal-medial thickening of the extracranial carotid artery. Circulation (1995) 1.36
Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med (2004) 1.34
High coronary artery calcium scores pose an extremely elevated risk for hard events. J Am Coll Cardiol (2002) 1.27
Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke (1996) 1.19
Acute coronary thrombosis--the role of plaque disruption and its initiation and prevention. Eur Heart J (1995) 1.18
Characterization of coronary atherosclerotic plaques by multidetector computed tomography. Am J Cardiol (2006) 1.13
Near-infrared spectroscopic characterization of human advanced atherosclerotic plaques. J Am Coll Cardiol (2002) 1.13
Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J (2008) 1.11
Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomography. Heart (2008) 1.10
The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int J Clin Pract (2007) 1.07
Noninvasive imaging of atherosclerotic lesions in apolipoprotein E-deficient and low-density-lipoprotein receptor-deficient mice with annexin A5. J Nucl Med (2006) 1.04
99mTc-annexin V imaging for in vivo detection of atherosclerotic lesions in porcine coronary arteries. J Nucl Med (2005) 0.92
Correlation of carotid atheromatous plaque inflammation with biomechanical stress: utility of USPIO enhanced MR imaging and finite element analysis. Atherosclerosis (2007) 0.91
99mTc-Annexin A5 for noninvasive characterization of atherosclerotic lesions: imaging and histological studies in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. Eur J Nucl Med Mol Imaging (2007) 0.90
Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. Am Heart J (2008) 0.82
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (2011) 4.67
Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA (2011) 3.97
Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol (2013) 3.25
Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart Association. Circulation (2010) 2.89
Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA (2013) 2.62
Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med (2008) 2.42
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis (2010) 2.39
Appropriate cardiac cath lab activation: optimizing electrocardiogram interpretation and clinical decision-making for acute ST-elevation myocardial infarction. Am Heart J (2010) 2.33
Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis (2010) 1.76
Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake. J Am Coll Cardiol (2012) 1.72
Targeting preschool children to promote cardiovascular health: cluster randomized trial. Am J Med (2012) 1.70
Effect of exercise treadmill testing and stress imaging on the triage of patients with chest pain: CHEER substudy. Mayo Clin Proc (2005) 1.69
Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging (2009) 1.66
Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial. Circulation (2012) 1.60
Authors' self-declared financial conflicts of interest do not impact the results of major cardiovascular trials. J Am Coll Cardiol (2013) 1.47
Emerging anti-inflammatory drugs for atherosclerosis. Expert Opin Emerg Drugs (2013) 1.43
Correlation between index electrocardiographic patterns and pre-intervention angiographic findings: insights from the HORIZONS-AMI trial. Catheter Cardiovasc Interv (2011) 1.41
Trends in the prevalence, awareness, treatment and control of high low density lipoprotein-cholesterol among United States adults from 1999-2000 through 2009-2010. Am J Cardiol (2013) 1.24
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J (2004) 1.19
Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol (2006) 1.14
Optimizing 18F-FDG PET/CT imaging of vessel wall inflammation: the impact of 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels. Eur J Nucl Med Mol Imaging (2013) 1.14
Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. Am J Cardiol (2008) 1.08
The complementary roles of dynamic contrast-enhanced MRI and 18F-fluorodeoxyglucose PET/CT for imaging of carotid atherosclerosis. Eur J Nucl Med Mol Imaging (2013) 1.02
Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study. JACC Cardiovasc Imaging (2011) 1.01
Quality of life after PCI vs CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial. JAMA (2013) 1.01
Arterial and fat tissue inflammation are highly correlated: a prospective 18F-FDG PET/CT study. Eur J Nucl Med Mol Imaging (2014) 0.99
Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V. Arch Intern Med (2007) 0.98
Risk for recurrent coronary heart disease and all-cause mortality among individuals with chronic kidney disease compared with diabetes mellitus, metabolic syndrome, and cigarette smokers. Am Heart J (2013) 0.92
Cardiovascular safety of biologic therapies for the treatment of RA. Nat Rev Rheumatol (2011) 0.92
Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes. Diabetes Care (2006) 0.92
The vulnerable plaque and acute coronary syndromes. Am J Med (2002) 0.91
Crushed clopidogrel administered via nasogastric tube has faster and greater absorption than oral whole tablets. J Interv Cardiol (2009) 0.88
Diabetes and aspirin: beware of underpowered negative trials. Nat Clin Pract Cardiovasc Med (2009) 0.88
Diabetes mellitus and acute coronary syndrome: lessons from randomized clinical trials. Curr Diab Rep (2012) 0.87
Assessing patient-reported outcomes and preferences for same-day discharge after percutaneous coronary intervention: results from a pilot randomized, controlled trial. Circ Cardiovasc Qual Outcomes (2013) 0.86
Long-term outcomes in non-diabetic patients with metabolic syndrome undergoing revascularization for multi-vessel coronary artery disease. Atherosclerosis (2007) 0.85
Elevated homocysteine levels in patients with end-stage renal disease. Mt Sinai J Med (2005) 0.85
Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. Eur Heart J (2007) 0.85
Outcomes in patients with chest pain evaluated in a chest pain unit: the chest pain evaluation in the emergency room study cohort. Am Heart J (2011) 0.84
Outcomes and care of patients with acute heart failure syndromes and cardiac troponin elevation. Circ Heart Fail (2013) 0.84
Association between physician follow-up and outcomes of care after chest pain assessment in high-risk patients. Circulation (2013) 0.84
Predictors of low clopidogrel adherence following percutaneous coronary intervention. Am J Cardiol (2011) 0.84
NSAIDs are associated with lower depression scores in patients with osteoarthritis. Am J Med (2013) 0.83
Biomarkers after risk stratification in acute chest pain (from the BRIC Study). Am J Cardiol (2012) 0.83
Long-term cardiovascular outcomes in patients with angina pectoris presenting with bundle branch block. Am J Cardiol (2011) 0.83
Diminished benefits of drug-eluting stents versus bare metal stents in patients with severe renal insufficiency. Nephron Clin Pract (2009) 0.82
Relation of high-density lipoprotein cholesterol to mortality after percutaneous coronary interventions in patients with low-density lipoprotein <70 mg/dl. Am J Cardiol (2008) 0.82
Chronic kidney disease as a risk factor for acute coronary syndromes in patients presenting to the emergency room with chest pain. Transl Res (2012) 0.82
Clustering of metabolic abnormalities among obese patients and mortality after percutaneous coronary intervention. Am J Cardiol (2011) 0.82
Promotion of cardiovascular health in preschool children: 36-month cohort follow-up. Am J Med (2013) 0.81
Awareness, treatment, and control of LDL cholesterol are lower among U.S. adults with undiagnosed diabetes versus diagnosed diabetes. Diabetes Care (2013) 0.81
Causes of death and re-hospitalization in cardiogenic shock. Acute Card Care (2007) 0.80
Is measuring C-reactive protein useful for guiding treatment in women > or = 60 years and men > or = 50 years of age? Am J Cardiol (2009) 0.80
The Future REvascularization Evaluation in patients with Diabetes mellitus: optimal management of Multivessel disease (FREEDOM) trial: clinical and angiographic profile at study entry. Am Heart J (2012) 0.80
Aspirin use is associated with an improved long-term survival in an unselected population presenting with unstable angina. Clin Cardiol (2010) 0.79
Associations between routine coronary computed tomographic angiography and reduced unnecessary hospital admissions, length of stay, recidivism rates, and invasive coronary angiography in the emergency department triage of chest pain. J Am Coll Cardiol (2013) 0.79
Cardiovascular effects of selective COX-2 inhibition: is there a class effect? The International COX-2 Study Group. J Rheumatol (2006) 0.79
Revascularization strategies in patients with diabetes. N Engl J Med (2013) 0.78
Prognostic significance of postprocedural sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial). Am J Cardiol (2011) 0.78
C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention. Am Heart J (2009) 0.78
Comparison of direct stenting with conventional stent implantation in acute myocardial infarction. Am J Cardiol (2011) 0.78
Cardiovascular disease in diabetics: pharmacology and revascularization. Mt Sinai J Med (2004) 0.78
Reply: Relevance of Indications for CABG in Evaluating the Effect of Dual Antiplatelet Therapy. J Am Coll Cardiol (2017) 0.77
Chagas disease as a mechanistic model for testing a novel hypothesis. Rev Soc Bras Med Trop (2008) 0.77
Time to welcome the elderly into clinical trials. Nat Clin Pract Cardiovasc Med (2008) 0.77
Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients. Thromb Haemost (2007) 0.77
Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema? Ther Adv Cardiovasc Dis (2008) 0.77
Optimal treatment of the diabetic patient with multivessel disease. Curr Cardiol Rep (2008) 0.77
Relation between the degree of procedural anticoagulation and complications after coronary stent implantation. Am J Cardiol (2003) 0.77
Meta-analysis of small trials: proceed with caution. Nat Clin Pract Nephrol (2008) 0.77
Balancing cardiovascular and gastrointestinal risks in patients with osteoarthritis receiving nonsteroidal anti‑inflammatory drugs. A summary of guidelines from an international expert group. Pol Arch Med Wewn (2016) 0.76
Noninvasive cardiovascular imaging in rheumatoid arthritis: current modalities and the emerging role of magnetic resonance and positron emission tomography imaging. Semin Arthritis Rheum (2011) 0.75
Acute coronary syndromes and diabetes mellitus: a winning ticket for prasugrel. Circulation (2008) 0.75
ACP Journal Club. Meta-analysis: Atorvastatin reduces CV events and increases new-onset diabetes in patients with coronary disease. Ann Intern Med (2013) 0.75
The PROSPECT of changing our approach to acute coronary syndromes. JACC Cardiovasc Imaging (2012) 0.75
Reply: Underutilization of High-Intensity Statin Therapy After Hospitalization for Coronary Heart Disease: A Cause for Concern, But a Few Words of Caution. J Am Coll Cardiol (2015) 0.75
Non-steroidal anti-inflammatory drugs and the heart. Heart (2010) 0.75
Rapid complete reversal of systemic hypoperfusion after intra-aortic balloon pump counterpulsation and survival in cardiogenic shock complicating an acute myocardial infarction. Am Heart J (2011) 0.75
Statins improve visual field alterations related to hypercholesterolemia. Atherosclerosis (2009) 0.75
Prognostic Significance of Post-CABG Enzyme Elevations. Anesth Analg (2017) 0.75
Characterizing young patients with diabetes and non-ST-segment elevation acute coronary syndromes. Diabetes Care (2007) 0.75
Left ventricular hypertrophy by electrocardiography and echocardiography in the African American Study of Kidney Disease Cohort Study. J Am Soc Hypertens (2012) 0.75
Does influenza vaccination influence cardiovascular complications? Expert Rev Cardiovasc Ther (2015) 0.75
Faster publication isn't always better. Nat Clin Pract Cardiovasc Med (2007) 0.75
Does acetylsalicylic acid or warfarin affect the accuracy of fecal occult blood tests? J Gastroenterol Hepatol (2013) 0.75
Thrombolysis In Myocardial Infarction (TIMI) risk score and mortality in patients with advanced chronic kidney disease and on dialysis. Am J Cardiol (2009) 0.75
Periprocedural myocardial enzyme elevation: prognostic implications for current practice. Curr Cardiol Rep (2012) 0.75
Getting to the heart of the matter: a trialist's approach to the use of nonsteroidal anti‑inflammatory drugs for patients with chronic pain syndromes. Pol Arch Med Wewn (2013) 0.75
Failing to ENHANCE science. Nat Clin Pract Cardiovasc Med (2008) 0.75
Does PCI reduce the occurrence of 'hard' clinical endpoints in patients with stable coronary artery disease? Nat Clin Pract Cardiovasc Med (2005) 0.75
Stress testing and troponin in unstable coronary syndromes: the status trial-clinical outcomes and resource use. Am Heart Hosp J (2006) 0.75
Meta-analysis of small trials: proceed with caution. Nat Clin Pract Cardiovasc Med (2007) 0.75
Hypercholesterolemia is associated with visual field alterations detectable with computerized perimetry. Atherosclerosis (2007) 0.75
Preoperative Intraaortic Balloon Pump Improves Early Outcomes Following High-Risk Coronary Artery Bypass Graft Surgery: A Meta-Analysis of Randomized Trials and Prospective Study Design. J Invasive Cardiol (2017) 0.75
Lumiracoxib, a highly selective COX-2 inhibitor. Expert Rev Clin Immunol (2005) 0.75
The incremental value of troponin-I testing in patients with intermediate risk unstable angina. Clin Cardiol (2004) 0.75
LDL cholesterol response and statin adherence among high-risk patients initiating treatment. Am J Manag Care (2016) 0.75